Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Oral, corresponding dose regimen according to study cohort (including Part A, Part B) .”In the company’s words, NCT07793019 on ClinicalTrials.gov
- Tested for
- Overweight, Obesity
- Main trialPhase 1
- “This is a randomized, investigator- and participant-blinded, placebo-controlled, parallel-group, dose-escalation Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of IBI3042, in healthy adult participants. Approximately 32 healthy participants will be enrolled across 4 single ascending dose groups, with 8 participants per group randomized in a 6:2 ratio to receive a single oral dose of IBI3042 or matching placebo. A sentinel-dosing design is used for the first dose cohort. Safety and PK data are assessed to support dose escalation…”In the company’s words, NCT07842393 on ClinicalTrials.gov
Other drugs for Overweight
- RetatrutideEli Lilly · Phase 3
- TradipitantVanda Pharmaceuticals · Phase 3
- LiraglutideNovo Nordisk · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- HRS-7535Hengrui · Kailera · Phase 3
- IN-B00009HK inno.N · Phase 3
Coming up2
- 3 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- 6 Sep 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | 3 Feb 2027 | A Study of IBI3042 in Healthy Adult Participants | |
| Phase 1Recruiting | 6 Sep 2027 | IBI3042 Study in Healthy Participants and Overweight or Obese Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026